Conmed (CNMD) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Leerink Partners Cuts Price Target on Conmed (CNMD) to $43; Reiterates Market Perform
October 28, 2016 9:04 AM EDTLeerink Partners maintained a Market Perform rating on CONMED (NASDAQ: CNMD), and cut the price target to $43.00 (from $47.00), following the company's 3Q earnings report. 3Q revenues of $185M beat $178M estimates, and organic growth of +0.8% beat +0.4% forecasts and marked an improvement vs. -1% in 2Q and -2% in 1Q. Airseal revenues... More



